SSTNIV, a syndecan-1-targeting peptide chimera, reverses immune suppression and inhibits myeloma progression

Key Points

• This research aims to evaluate the effectiveness of SSTNIV in reversing immune suppression and inhibiting myeloma progression.
• Used a peptide chimera, SSTNIV, targeting syndecan-1.
• Evaluated its anti-myeloma activity in advanced and relapsed/refractory myeloma.
• Assessed immune restoration effects.
• SSTNIV significantly reversed immune suppression.
• Showed a marked reduction in myeloma progression.
• Indicated potential as a promising therapeutic strategy.